Cargando…
Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma
OBJECTIVE: To explore the effect of dysregulation of epigenetic regulator EZH1 and EZH2 on the proliferation in MCL and the underlying mechanisms. METHODS: In this study, we elucidated the role of EZH1 and EZH2 overexpression by immunohistochemistry and correlated them to clinical outcome in 41 MCL...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Anti-Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743615/ https://www.ncbi.nlm.nih.gov/pubmed/31565482 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0380 |
_version_ | 1783451299441803264 |
---|---|
author | Li, Wei Bi, Chengfeng Han, Yating Tian, Tian Wang, Xianhuo Bao, Huijing Xu, Xiaoying Zhang, Xuhan Liu, Lu Zhang, Weiwei Gao, Hai Wang, Huaqing Zhang, Huilai Meng, Bin Wang, Xi Fu, Kai |
author_facet | Li, Wei Bi, Chengfeng Han, Yating Tian, Tian Wang, Xianhuo Bao, Huijing Xu, Xiaoying Zhang, Xuhan Liu, Lu Zhang, Weiwei Gao, Hai Wang, Huaqing Zhang, Huilai Meng, Bin Wang, Xi Fu, Kai |
author_sort | Li, Wei |
collection | PubMed |
description | OBJECTIVE: To explore the effect of dysregulation of epigenetic regulator EZH1 and EZH2 on the proliferation in MCL and the underlying mechanisms. METHODS: In this study, we elucidated the role of EZH1 and EZH2 overexpression by immunohistochemistry and correlated them to clinical outcome in 41 MCL patients. Quantitative real-time PCR and Western blot were applied to confirm the level of EZH1 and EZH2 in well-characterized MCL cell lines which were compared to those of naïve B cells. Then we manipulated the expression of EZH1 and EZH2 in MCL cells using CRISPR/Cas9 system to directly investigate their functional roles in MCL. We also evaluated the effect of two small molecule selective inhibitors, EPZ005687 and UNC1999, on MCL cell proliferation, cell cycle distribution and apoptosis in vitro. Finally, we performed RNA-sequencing (RNA-Seq) and Chromatin immunoprecipitation (ChIP) assay to further gain insight into the underlying molecular mechanisms. RESULTS: We found that EZH2 protein is overexpressed in approximately half of this cohort of MCL cases. More importantly, the overexpression of EZH2 is associated with poor OS in the patients. Nevertheless, simple EZH2 depletion in vitro has little impact on the viability of MCL cells, predominantly because of the consequent up-regulation of EZH1. Consistently, UNC1999, a dual EZH1/2 inhibitor, unlike the EZH2 selective inhibitor EPZ005687, exerts a potent inhibitory effect on MCL cells. Furthermore, we discover CDKN1C and TP53INP1 as the two important cell cycle regulators, the expression of which are repressed by EZH1/2 mediated epigenetic regulation and are restored by EZH1/2 dual inhibition. CONCLUSIONS: Our study suggests that EZH2 participates in the pathogenesis of MCL which may serve as a potential biomarker for prognosis prediction. The dual inhibition of EZH1/2 is a promising therapeutic strategy for MCL. |
format | Online Article Text |
id | pubmed-6743615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Chinese Anti-Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-67436152019-09-27 Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma Li, Wei Bi, Chengfeng Han, Yating Tian, Tian Wang, Xianhuo Bao, Huijing Xu, Xiaoying Zhang, Xuhan Liu, Lu Zhang, Weiwei Gao, Hai Wang, Huaqing Zhang, Huilai Meng, Bin Wang, Xi Fu, Kai Cancer Biol Med Original Article OBJECTIVE: To explore the effect of dysregulation of epigenetic regulator EZH1 and EZH2 on the proliferation in MCL and the underlying mechanisms. METHODS: In this study, we elucidated the role of EZH1 and EZH2 overexpression by immunohistochemistry and correlated them to clinical outcome in 41 MCL patients. Quantitative real-time PCR and Western blot were applied to confirm the level of EZH1 and EZH2 in well-characterized MCL cell lines which were compared to those of naïve B cells. Then we manipulated the expression of EZH1 and EZH2 in MCL cells using CRISPR/Cas9 system to directly investigate their functional roles in MCL. We also evaluated the effect of two small molecule selective inhibitors, EPZ005687 and UNC1999, on MCL cell proliferation, cell cycle distribution and apoptosis in vitro. Finally, we performed RNA-sequencing (RNA-Seq) and Chromatin immunoprecipitation (ChIP) assay to further gain insight into the underlying molecular mechanisms. RESULTS: We found that EZH2 protein is overexpressed in approximately half of this cohort of MCL cases. More importantly, the overexpression of EZH2 is associated with poor OS in the patients. Nevertheless, simple EZH2 depletion in vitro has little impact on the viability of MCL cells, predominantly because of the consequent up-regulation of EZH1. Consistently, UNC1999, a dual EZH1/2 inhibitor, unlike the EZH2 selective inhibitor EPZ005687, exerts a potent inhibitory effect on MCL cells. Furthermore, we discover CDKN1C and TP53INP1 as the two important cell cycle regulators, the expression of which are repressed by EZH1/2 mediated epigenetic regulation and are restored by EZH1/2 dual inhibition. CONCLUSIONS: Our study suggests that EZH2 participates in the pathogenesis of MCL which may serve as a potential biomarker for prognosis prediction. The dual inhibition of EZH1/2 is a promising therapeutic strategy for MCL. Chinese Anti-Cancer Association 2019-08 /pmc/articles/PMC6743615/ /pubmed/31565482 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0380 Text en Copyright 2019 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Original Article Li, Wei Bi, Chengfeng Han, Yating Tian, Tian Wang, Xianhuo Bao, Huijing Xu, Xiaoying Zhang, Xuhan Liu, Lu Zhang, Weiwei Gao, Hai Wang, Huaqing Zhang, Huilai Meng, Bin Wang, Xi Fu, Kai Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma |
title | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma
|
title_full | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma
|
title_fullStr | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma
|
title_full_unstemmed | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma
|
title_short | Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma
|
title_sort | targeting ezh1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(cdkn1c) and tp53inp1 in mantle cell lymphoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743615/ https://www.ncbi.nlm.nih.gov/pubmed/31565482 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0380 |
work_keys_str_mv | AT liwei targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT bichengfeng targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT hanyating targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT tiantian targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT wangxianhuo targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT baohuijing targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT xuxiaoying targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT zhangxuhan targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT liulu targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT zhangweiwei targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT gaohai targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT wanghuaqing targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT zhanghuilai targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT mengbin targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT wangxi targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma AT fukai targetingezh12inducescellcyclearrestandinhibitscellproliferationthroughreactivationofp57cdkn1candtp53inp1inmantlecelllymphoma |